Graphical Displays for Modeling Population Data

Pharmacometrics: The Science of Quantitative Pharmacology

Volumn , Issue , 2006, Pages 183-222

  Jonsson, E Niclas ^a   Karlsson, Mats O ^b   Milligan, Peter A ^c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UPPSALA UNIVERSITY   (Sweden)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Confidence intervals; Covariate model; Covariates; Data checkout; Exploratory data analysis; Goodness of fit plots; Individualized dosing; Inter individual variability; IPRED; IWRES; NONMEM; Plotting variables; Prediction; PREDPP library; Residual diagnostic plots; Residual variability; Simulation; Time scales; Visualization; WRES

Indexed keywords

EID: 84889420924     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470087978.ch7     Document Type: Chapter

References (19)

1. W. S. Cleveland. Visualizing Data. Hobart Press, Summit, NJ, 1993.
2. L. Brynne, M. O. Karlsson, and L. K. Paalzow, Concentration-effect relationship of l-propranolol and metoprolol in spontaneous hypertensive rats after exercise-induced tachycardia. J Pharmacol Exp Ther 286:1152-1158 (1998).
3. L. Brynne, L. K. Paalzow, and M. O. Karlsson, Consequence of exercise on the cardiovascular effects of l-propranolol in spontaneously hypertensive rats. J Pharmacol Exp Ther 294:1201-1208 (2000).
4. M. O. Karlsson and L. B. Sheiner, The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 21:735-750 (1993).
5. E. I. Ette, Statistical graphics in pharmacokinetics and pharmacodynamics: a tutorial. Ann Pharmacother 32:818-828 (1998).
6. E. I. Ette and T. M. Ludden, Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res 12:1845-1855 (1995).
7. E. I. Ette, P. Williams, E. Fadiran, F. O. Ajayi, and L. C. Onyiah, The process of knowledge discovery from large pharmacokinetic data sets. J Clin Pharmacol 41:25-34 (2001).
8. E. N. Jonsson and M. O. Karlsson, Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51-64 (1999).
9. M. O. Karlsson, E. N. Jonsson, C. G. Wiltse, and J. R. Wade, Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm 26:207-246 (1998).
10. U. Wahlby, A. H. Thomson, P. A. Milligan, and M. O. Karlsson, Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. Br J Clin Pharmacol 58:367-377 (2004).
11. S. L. Beal and L. B. Sheiner, NONMEM Users Guides. Globomax, Inc., Baltimore, MD, 1989-1998.
12. M. O. Karlsson, S. L. Beal, and L. B. Sheiner, Three new residual error models for population PK/PD analyses. J Pharmacokinet Biopharm 23:651-672 (1995).
13. R. J. Carroll and D. Ruppert, Transformation and weighting in regression. Chapman & Hall, New York, 1988.
14. J. Gabrielsson and D. Weiner, Pharmacokinetic and pharmacodynamic data analysis. Swedish Pharmaceutical Press, Stockholm, Sweden, 1997.
15. E. H. Cox, C. Veyrat-Follet, S. L. Beal, E. Fuseau, S. Kenkare, and L. B. Sheiner, A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-toevent pharmacodynamic responses: the antiemetic effect of ondansetron. J Pharmacokinet Biopharm 27:625-644 (1999).
16. L. B. Sheiner, A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clin Pharmacol Ther 56:309-322 (1994).
17. P. H. Zingmark, M. Ekblom, T. Odergren, T. Ashwood, P. Lyden, M. O. Karlsson, and E. N. Jonsson, Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients. Br J Clin Pharmacol 56:173-183 (2003).
18. S. Jönsson and M. O. Karlsson, A rational approach for selection of optimal covariatebased dosing strategies. Clin Pharmacol Ther 73:7-19 (2003).
19. M. Chambers and J. Hastie, Statistical Models in S. Chapman & Hall, New York, 1993.